Biotech Values

[DewDiligence]

Effient fails to show superiority to Plavix in low-risk ACS patients:

http://finance.yahoo.com/news/daiichi-sankyo-lilly-announce-trilogy-060000980.html

Daiichi Sankyo Company, Limited and Eli Lilly and Company today announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in patients with unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI), who were managed medically without an artery-opening procedure. At 30 months, 13.9 percent of prasugrel patients vs. 16.0 percent of clopidogrel patients experienced the combined primary endpoint of heart attack, stroke or cardiovascular (CV) death in patients under 75 years of age, the primary analysis population (HR=0.91; 95% CI: 0.79-1.05). This outcome was not statistically significant (P=0.21).

Effient has been a commercial bust, logging less than $500M of annualized worldwide sales in recent quarters (i.e. only 5% of Plavix’s peak sales), and this new study certainly won’t help. More impetus for LLY to engage in some kind of financial engineering, as discussed in #msg-78887599.